Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ablynx Collaborates With Merck to Develop Therapeutic Nanobody Candidates

Published: Tuesday, October 02, 2012
Last Updated: Tuesday, October 02, 2012
Bookmark and Share
Companies to develop and commercialise Nanobody® candidates directed towards a voltage gated ion channel with the option to develop and commercialise a Nanobody to a second target.

Under the terms of the agreement, Merck gains exclusive global rights to Nanobodies against the selected target, with an option for similar rights to a second target. Upon signing, Merck will pay Ablynx a EUR6.5 million upfront payment and a EUR2 million fee for research funding. In addition, Ablynx will be eligible to receive up to EUR448 million in research, regulatory and commercial milestone payments associated with the progress of multiple candidates as well as tiered royalties on any products derived from the collaboration. Ablynx will be responsible for the discovery of Nanobody candidates and Merck will be responsible for the research, development, manufacturing and commercialisation of any Nanobody product resulting from the collaboration.

Dr Edwin Moses, Chairman and CEO of Ablynx said:

"We are delighted to initiate this collaboration with Merck in the area of ion channels where to date monoclonal antibodies have demonstrated little success. Due to the formatting flexibility of Nanobodies, we are able to combine antibody-like selectivity and multi-specificity in one molecule, making them ideal candidates for ion channel modulators. This agreement reflects the potential power of the Nanobody platform and the considerable success we have had to date with seven Nanobody programmes at the clinical development stage."

"We are excited to be working with Ablynx to evaluate the potential of the Nanobody technology directed towards this challenging ion channel target," said Richard Hargreaves, Ph.D., Vice President and Head of Neuroscience Discovery Research at Merck.

About Ablynx' expertise in ion channels

Ablynx has already demonstrated modulation of ion channel activity in electrophysiology assays and has identified functional Nanobodies against both voltage-gated and ligand-gated ion channels. Nanobodies can be generated to have either an agonistic (enhancing) or antagonistic (blocking) effect.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!